Effects of redox reagents and arsenical compounds on [3H]-cytisine binding to immunoisolated nicotinic acetylcholine receptors from chick brain containing alpha 4 beta 2 subunits.
All known nicotinic receptor alpha subunits include a conserved disulfide bond that is essential for function and is a site for labeling via biochemical modification. In an effort to develop a universal ligand for all subtypes of nicotinic receptors, we previously studied the effects of arsenylation with two compounds, p-aminophenyldichloroarsine (APA) and bromoacetyl-p-aminophenylarsenoxide (BAPA) on nicotinic receptors from Torpedo electroplax. Here we apply these reagents to immunoisolated receptors containing alpha 4, beta 2, and possibly other subunits from chick brain that bind [3H]cytisine with high affinity (KD approximately 5 nM). These are distinct from another receptor subtype that also binds [3H]cytisine and [3H]nicotine and can be arsenylated with APA, but instead contains alpha 5, beta 2, and probably other subunits. Reduction of alpha 4 beta 2 receptors with dithiothreitol blocked [3H]cytisine binding and this effect was reversed upon reoxidation by dithiobisnitrobenzoic acid. APA or BAPA prevented the dithiobisnitrobenzoic acid reactivation of dithiothreitol-treated receptors with IC50 values of 15 and 70 nM, respectively. However, the antiarsenical dimercaptopropanesulfonic acid restored function to APA- or BAPA- "arsenylated" receptors (EC50 approximately 100 microM). APA-treated receptors remained blocked for up to 24 h, but treatment with dimercaptopropanesulfonic acid at any time restored [3H]cytisine binding. APA treatment of reduced receptors protected against irreversible alkylation by bromoacetylcholine, indicating that arsenylation occurs at least in part in the agonist binding site. Thus, these reagents have similar effects on different nicotinic receptor subtypes from both muscle and nerves.(ABSTRACT TRUNCATED AT 250 WORDS)
Rossant
C J
CJ
Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115.
Lindstrom
J
J
Loring
R H
RH
D000470:Alkaloids / Q000378:metabolism*; D000478:Alkylation; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D001152:Arsenicals / Q000494:pharmacology*; D001392:Azocines; D001923:Brain Chemistry; D002645:Chickens; D004228:Dithionitrobenzoic Acid / Q000494:pharmacology; D004229:Dithiothreitol / Q000494:pharmacology*; D007163:Immunosorbent Techniques; D010084:Oxidation-Reduction; D011807:Quinolizines; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification / Q000378:metabolism*; D014316:Tritium; D014494:Unithiol / Q000494:pharmacology; D000093843:Quinolizidine Alkaloids
D000470:Alkaloids; D000911:Antibodies, Monoclonal; D001152:Arsenicals; D001392:Azocines; D004228:Dithionitrobenzoic Acid; D004229:Dithiothreitol; D011807:Quinolizines; D011978:Receptors, Nicotinic; D014316:Tritium; D014494:Unithiol; C004712:cytisine; D000093843:Quinolizidine Alkaloids; C053801:4-aminophenyldichloroarsine; C031672:4-((bromoacetyl)amino)phenyl arsenoxide